CoChat
Cited by 94

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

The cannabinoid system and microglia in health and disease

Duffy, Samuel S., Hayes, Jessica P., Fiore, Nathan T., Moalem-Taylor, Gila · 2021 · Neuropharmacology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2021.108555

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 65 references

Research works printed but not linked: 195

  1. Alberti, 2017, (-)-β-Caryophyllene, a CB2 receptor-selective phytocannabinoid, suppresses motor paralysis and neuroinflammation in a murine model of multiple sclerosis, Int. J. Mol. Sci., 18, 10.3390/ijms18040691 · DOI
  2. Anavi-Goffer, 2012, Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids, J. Biol. Chem., 287, 91, 10.1074/jbc.M111.296020 · DOI
  3. Araujo, 2019, The endocannabinoid system as a window into microglial biology and its relationship to autism, Front. Cell. Neurosci., 13, 424, 10.3389/fncel.2019.00424 · DOI
  4. Arévalo-Martín, 2003, Therapeutic action of cannabinoids in a murine model of multiple sclerosis, J. Neurosci., 23, 2511, 10.1523/JNEUROSCI.23-07-02511.2003 · DOI · Paper page
  5. Askari, 2019, Combination of Imipramine, a sphingomyelinase inhibitor, and β-caryophyllene improve their therapeutic effects on experimental autoimmune encephalomyelitis (EAE), Int. Immunopharm., 77, 105923, 10.1016/j.intimp.2019.105923 · DOI
  6. Aso, 2016, Cannabinoid receptor 2 participates in amyloid-β processing in a mouse model of alzheimer's disease but plays a minor role in the therapeutic properties of a cannabis-based medicine, J Alzheimers Dis, 51, 489, 10.3233/JAD-150913 · DOI
  7. Bauer, 2019, Inflammation in psychiatric disorders: what comes first?, Ann. N. Y. Acad. Sci., 1437, 57, 10.1111/nyas.13712 · DOI · Paper page
  8. Baxter, 2007, The origin and application of experimental autoimmune encephalomyelitis, Nat. Rev. Immunol., 7, 904, 10.1038/nri2190 · DOI · Paper page
  9. Benito, 2003, Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains, J. Neurosci., 23, 11136, 10.1523/JNEUROSCI.23-35-11136.2003 · DOI · Paper page
  10. Bernstein, 2009, Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy, Expert Rev. Neurother., 9, 1059, 10.1586/ern.09.59 · DOI · Paper page
  11. Bie, 2018, An overview of the cannabinoid type 2 receptor system and its therapeutic potential, Curr. Opin. Anaesthesiol., 31, 407, 10.1097/ACO.0000000000000616 · DOI · Paper page
  12. Bilsland, 2006, Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice, Faseb. J., 20, 1003, 10.1096/fj.05-4743fje · DOI · Paper page
  13. Bilsland, 2008, The endocannabinoid system in amyotrophic lateral sclerosis, Curr. Pharmaceut. Des., 14, 2306, 10.2174/138161208785740081 · DOI
  14. Borowska-Fielding, 2018, Revisiting cannabinoid receptor 2 expression and function in murine retina, Neuropharmacology, 141, 21, 10.1016/j.neuropharm.2018.08.007 · doi:10.1016/j.neuropharm.2018.08.007
  15. Burgos, 2012, Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells, Eur. J. Pharmacol., 682, 62, 10.1016/j.ejphar.2012.02.008 · DOI
  16. Cabral, 2005, Cannabinoid receptors in microglia of the central nervous system: immune functional relevance, J. Leukoc. Biol., 78, 1192, 10.1189/jlb.0405216 · DOI · Paper page
  17. Carrier, 2004, Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism, Mol. Pharmacol., 65, 999, 10.1124/mol.65.4.999 · DOI · Paper page
  18. Carrillo-Salinas, 2014, A cannabigerol derivative suppresses immune responses and protects mice from experimental autoimmune encephalomyelitis, PloS One, 9, 10.1371/journal.pone.0094733 · DOI
  19. Cass, 2014, CB1 cannabinoid receptor stimulation during adolescence impairs the maturation of GABA function in the adult rat prefrontal cortex, Mol. Psychiatr., 19, 536, 10.1038/mp.2014.14 · DOI · Paper page
  20. Chen, 2018, Microglia in pain: detrimental and protective roles in pathogenesis and resolution of pain, Neuron, 100, 1292, 10.1016/j.neuron.2018.11.009 · DOI · Paper page
  21. Chiu, 2013, A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model, Cell Rep., 4, 385, 10.1016/j.celrep.2013.06.018 · DOI · Paper page
  22. Chung, 2011, Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation, J. Immunol., 187, 6508, 10.4049/jimmunol.1102435 · DOI
  23. Chung, 2016, CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease, Exp. Mol. Med., 48, 10.1038/emm.2015.100 · DOI · Paper page
  24. Concannon, 2015, Differential upregulation of the cannabinoid CB₂ receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease, Exp. Neurol., 269, 133, 10.1016/j.expneurol.2015.04.007 · DOI
  25. Concannon, 2016, Upregulation of the cannabinoid CB2 receptor in environmental and viral inflammation-driven rat models of Parkinson's disease, Exp. Neurol., 283, 204, 10.1016/j.expneurol.2016.06.014 · DOI
  26. Contestabile, 2011, The history of the cholinergic hypothesis, Behav. Brain Res., 221, 334, 10.1016/j.bbr.2009.12.044 · DOI · Paper page
  27. Correa, 2011, The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells, Brain Behav. Immun., 25, 736, 10.1016/j.bbi.2011.01.020 · DOI
  28. Corsi-Zuelli, 2017, Neuroimmune interactions in schizophrenia: focus on vagus nerve stimulation and activation of the alpha-7 nicotinic acetylcholine receptor, Front. Immunol., 8, 618, 10.3389/fimmu.2017.00618 · DOI
  29. de Lago, 2012, Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects, Neuropharmacology, 62, 2299, 10.1016/j.neuropharm.2012.01.030 · DOI
  30. Deleidi, 2010, The Toll-like receptor-3 agonist polyinosinic:polycytidylic acid triggers nigrostriatal dopaminergic degeneration, J. Neurosci., 30, 16091, 10.1523/JNEUROSCI.2400-10.2010 · DOI
  31. DeMarco, 2008, Chapter 1 - anatomy, physiology, and effects of pain, 3
  32. Di Giorgio, 2008, Human embryonic stem cell-derived motor neurons are sensitive to the toxic effect of glial cells carrying an ALS-causing mutation, Cell Stem Cell, 3, 637, 10.1016/j.stem.2008.09.017 · DOI · Paper page
  33. Di Marzo, 2015, Endocannabinoid signalling and the deteriorating brain, Nat. Rev. Neurosci., 16, 30, 10.1038/nrn3876 · DOI · Paper page
  34. Dickson, 2012, Parkinson's disease and parkinsonism: neuropathology, Cold Spring Harb Perspect Med, 2, 10.1101/cshperspect.a009258 · DOI · Paper page
  35. Duffy, 2014, The contribution of immune and glial cell types in experimental autoimmune encephalomyelitis and multiple sclerosis, Mult Scler Int, 2014, 285245
  36. Duncan, 2014, Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms, Mov. Disord., 29, 195, 10.1002/mds.25664 · DOI · Paper page
  37. Ehrhart, 2005, Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation, J. Neuroinflammation, 2, 29, 10.1186/1742-2094-2-29 · DOI · Paper page
  38. El-Alfy, 2010, Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L, Pharmacol. Biochem. Behav., 95, 434, 10.1016/j.pbb.2010.03.004 · DOI · Paper page
  39. ElBatsh, 2012, Anxiogenic-like effects of chronic cannabidiol administration in rats, Psychopharmacology (Berlin), 221, 239, 10.1007/s00213-011-2566-z · DOI
  40. Espejo-Porras, 2019, Targeting glial cannabinoid CB, Br. J. Pharmacol., 176, 1585
  41. Espejo-Porras, 2015, Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders, J. Neuroimmune Pharmacol., 10, 233, 10.1007/s11481-015-9602-4 · DOI
  42. Esposito, 2007, Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence, J. Pharmacol. Exp. Therapeut., 322, 1144, 10.1124/jpet.107.121566 · DOI
  43. Fakhfouri, 2012, WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway, Neuropharmacology, 63, 653, 10.1016/j.neuropharm.2012.05.013 · DOI
  44. Fernández-Suárez, 2014, Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model, Neurobiol. Aging, 35, 2603, 10.1016/j.neurobiolaging.2014.05.021 · DOI
  45. Foran, 2009, Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis, Antioxidants Redox Signal., 11, 1587, 10.1089/ars.2009.2444 · DOI · Paper page
  46. Franco, 2019, Potentiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists, Glia, 67, 2410, 10.1002/glia.23694 · DOI
  47. Franco, 2019, Potentiation of cannabinoid signaling in microglia by adenosine A, Glia, 67, 2410, 10.1002/glia.23694 · DOI
  48. Franklin, 2003, Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormal-cannabidiol-sensitive receptors, Eur. J. Pharmacol., 474, 195, 10.1016/S0014-2999(03)02074-0 · DOI
  49. Frost, 2016, Microglia: architects of the developing nervous system, Trends Cell Biol., 26, 587, 10.1016/j.tcb.2016.02.006 · DOI · Paper page
  50. Gao, 2008, Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration, J. Neurosci., 28, 7687, 10.1523/JNEUROSCI.0143-07.2008 · DOI · Paper page
  51. García, 2011, Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease, Br. J. Pharmacol., 163, 1495, 10.1111/j.1476-5381.2011.01278.x · DOI · Paper page
  52. García-Gutiérrez, 2011, Overexpression of CB2 cannabinoid receptors decreased vulnerability to anxiety and impaired anxiolytic action of alprazolam in mice, J. Psychopharmacol., 25, 111, 10.1177/0269881110379507 · DOI · Paper page
  53. García-Gutiérrez, 2018, Alterations in gene and protein expression of cannabinoid CB(2) and GPR55 receptors in the dorsolateral prefrontal cortex of suicide victims, Neurotherapeutics, 15, 796, 10.1007/s13311-018-0610-y · DOI
  54. Ginhoux, 2010, Fate mapping analysis reveals that adult microglia derive from primitive macrophages, Science, 330, 841, 10.1126/science.1194637 · DOI · Paper page
  55. Goldenberg, 2012, Multiple sclerosis review, P T, 37, 175
  56. Gomes, 2014, Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia, Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyu018 · DOI · Paper page
  57. Granja, 2012, A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis, J. Neuroimmune Pharmacol., 7, 1002, 10.1007/s11481-012-9399-3 · DOI · Paper page
  58. Gómez-Gálvez, 2016, Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 64, 200, 10.1016/j.pnpbp.2015.03.017 · DOI · Paper page
  59. Habib, 2011, Emerging drugs for amyotrophic lateral sclerosis, Expet Opin. Emerg. Drugs, 16, 537, 10.1517/14728214.2011.604312 · DOI
  60. Haight, 2019, Microglial modulation as a target for chronic pain: from the bench to the bedside and back, Anesth. Analg., 128, 737, 10.1213/ANE.0000000000004033 · DOI
  61. Hardiman, 2011, Clinical diagnosis and management of amyotrophic lateral sclerosis, Nat. Rev. Neurol., 7, 639, 10.1038/nrneurol.2011.153 · DOI · Paper page
  62. Henstridge, 2010, GPR55 ligands promote receptor coupling to multiple signalling pathways, Br. J. Pharmacol., 160, 604, 10.1111/j.1476-5381.2009.00625.x · DOI · Paper page
  63. Hickman, 2013, The microglial sensome revealed by direct RNA sequencing, Nat. Neurosci., 16, 1896, 10.1038/nn.3554 · DOI · Paper page
  64. Hill, 2009, The endocannabinoid system and the treatment of mood and anxiety disorders, CNS Neurol. Disord. - Drug Targets, 8, 451, 10.2174/187152709789824624 · DOI
  65. Horti, 2010, Synthesis and biodistribution of [11C]A-836339, a new potential radioligand for PET imaging of cannabinoid type 2 receptors (CB2), Bioorg. Med. Chem., 18, 5202, 10.1016/j.bmc.2010.05.058 · DOI
  66. Howlett, 1986, Involvement of Gi in the inhibition of adenylate cyclase by cannabimimetic drugs, Mol. Pharmacol., 29, 307, 10.1016/S0026-895X(25)10219-8 · DOI · Paper page
  67. Hu, 2015, Microglial and macrophage polarization-new prospects for brain repair, Nat. Rev. Neurol., 11, 56, 10.1038/nrneurol.2014.207 · DOI · Paper page
  68. Javed, 2016, Cannabinoid type 2 (CB2) receptors activation protects against oxidative stress and neuroinflammation associated dopaminergic neurodegeneration in rotenone model of Parkinson's disease, Front. Neurosci., 10, 321, 10.3389/fnins.2016.00321 · DOI · Paper page
  69. Jeong, 2016, High-resolution transcriptome analysis reveals neuropathic pain gene-expression signatures in spinal microglia after nerve injury, Pain, 157, 964, 10.1097/j.pain.0000000000000470 · DOI
  70. Ji, 2013, Glia and pain: is chronic pain a gliopathy?, Pain, 154, S10, 10.1016/j.pain.2013.06.022 · DOI · Paper page
  71. Jin, 2003, p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain, J. Neurosci., 23, 4017, 10.1523/JNEUROSCI.23-10-04017.2003 · DOI · Paper page
  72. Johnston, 2006, Amyotrophic lateral sclerosis in an urban setting: a population based study of inner city London, J. Neurol., 253, 1642, 10.1007/s00415-006-0195-y · DOI · Paper page
  73. Kalia, 2015, Parkinson's disease, Lancet, 386, 896, 10.1016/S0140-6736(14)61393-3 · DOI · Paper page
  74. Kato, 2016, Pattern recognition receptors in chronic pain: mechanisms and therapeutic implications, Eur. J. Pharmacol., 788, 261, 10.1016/j.ejphar.2016.06.039 · DOI
  75. Kim, 2006, AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis, Eur. J. Pharmacol., 542, 100, 10.1016/j.ejphar.2006.05.025 · DOI
  76. Kong, 2014, Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS, Cell. Immunol., 287, 1, 10.1016/j.cellimm.2013.11.002 · DOI
  77. Koppel, 2014, CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer's disease, Mol. Med., 20, 29, 10.2119/molmed.2013.00140.revised · DOI
  78. Kozela, 2011, Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice, Br. J. Pharmacol., 163, 1507, 10.1111/j.1476-5381.2011.01379.x · DOI · Paper page
  79. Kreutzberg, 1996, Microglia: a sensor for pathological events in the CNS, Trends Neurosci., 19, 312, 10.1016/0166-2236(96)10049-7 · DOI · Paper page
  80. Lafenêtre, 2007, The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction, Pharmacol. Res., 56, 367, 10.1016/j.phrs.2007.09.006 · DOI
  81. Lauckner, 2008, GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current, Proc. Natl. Acad. Sci. U. S. A., 105, 2699, 10.1073/pnas.0711278105 · DOI · Paper page
  82. Le, 2016, Protective microglia and their regulation in Parkinson's disease, Front. Mol. Neurosci., 9, 89, 10.3389/fnmol.2016.00089 · DOI
  83. Lee, 2010, Alpha-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1, J. Immunol., 185, 615, 10.4049/jimmunol.0903480 · DOI · Paper page
  84. Li, 2019, CB2 cannabinoid receptor agonist ameliorates novel object recognition but not spatial memory in transgenic APP/PS1 mice, Neurosci. Lett., 707, 134286, 10.1016/j.neulet.2019.134286 · DOI
  85. Lisboa, 2016, Microglial cells as a link between cannabinoids and the immune hypothesis of psychiatric disorders, Front. Neurol., 7, 5, 10.3389/fneur.2016.00005 · DOI
  86. Lisboa, 2018, Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2, Neuropsychopharmacology, 43, 1924, 10.1038/s41386-018-0064-2 · DOI
  87. Liu, 2017, TNF-α differentially regulates synaptic plasticity in the Hippocampus and spinal cord by microglia-dependent mechanisms after peripheral nerve injury, J. Neurosci., 37, 871, 10.1523/JNEUROSCI.2235-16.2016 · DOI · Paper page
  88. Lopez-Rodriguez, 2014, Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats, Br. J. Pharmacol., 171, 1435, 10.1111/bph.12519 · DOI
  89. Lou, 2018, The inhibition of CB, J. Neuroimmunol., 317, 37, 10.1016/j.jneuroim.2018.02.001 · DOI
  90. Lourbopoulos, 2011, Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis, Brain Res., 1390, 126, 10.1016/j.brainres.2011.03.020 · DOI
  91. Luongo, 2013, Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice, CNS Neurol. Disord. - Drug Targets, 12, 45, 10.2174/1871527311312010009 · doi:10.2174/1871527311312010009
  92. Luongo, 2010, 1-(2',4'-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice, Neurobiol. Dis., 37, 177, 10.1016/j.nbd.2009.09.021 · DOI
  93. López, 2018, Cannabinoid CB, J. Neuroinflammation, 15, 158, 10.1186/s12974-018-1174-9 · DOI · Paper page
  94. Lü, 2004, [Effect of clozapine and risperidone on serum cytokine levels in patients with first-episode paranoid schizophrenia], Di Yi Jun Yi Da Xue Xue Bao, 24, 1251
  95. Ma, 2015, Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling, Biochem. Biophys. Res. Commun., 458, 92, 10.1016/j.bbrc.2015.01.073 · DOI
  96. Mackie, 1992, Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells, Proc. Natl. Acad. Sci. U. S. A., 89, 3825, 10.1073/pnas.89.9.3825 · DOI · Paper page
  97. Malek, 2015, Anandamide, acting via CB2 receptors, alleviates LPS-induced neuroinflammation in rat primary microglial cultures, Neural Plast., 130639
  98. Mangieri, 2007, Enhancement of endocannabinoid signaling and the pharmacotherapy of depression, Pharmacol. Res., 56, 360, 10.1016/j.phrs.2007.09.003 · DOI
  99. Manterola, 2018, Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination, Biochem. Pharmacol., 157, 189, 10.1016/j.bcp.2018.07.042 · DOI
  100. Martín-Moreno, 2011, Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease, Mol. Pharmacol., 79, 964, 10.1124/mol.111.071290 · DOI · Paper page
  101. Masters, 2012, Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease, Cold Spring Harb Perspect Med, 2, a006262, 10.1101/cshperspect.a006262 · DOI · Paper page
  102. McCabe, 2017, Time-course of striatal Toll-like receptor expression in neurotoxic, environmental and inflammatory rat models of Parkinson's disease, J. Neuroimmunol., 310, 103, 10.1016/j.jneuroim.2017.07.007 · DOI
  103. Mecha, 2016, Microglia activation states and cannabinoid system: therapeutic implications, Pharmacol. Ther., 166, 40, 10.1016/j.pharmthera.2016.06.011 · DOI · Paper page
  104. Mecha, 2015, Endocannabinoids drive the acquisition of an alternative phenotype in microglia, Brain Behav. Immun., 49, 233, 10.1016/j.bbi.2015.06.002 · DOI · Paper page
  105. Mecha, 2013, Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors, Neurobiol. Dis., 59, 141, 10.1016/j.nbd.2013.06.016 · DOI · Paper page
  106. Mecha, 2018, 2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs, Glia, 66, 1447, 10.1002/glia.23317 · DOI
  107. Mestre, 2005, Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis, J. Neurochem., 92, 1327, 10.1111/j.1471-4159.2004.02979.x · DOI
  108. Miyaoka, 2007, Possible antipsychotic effects of minocycline in patients with schizophrenia, Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 31, 304, 10.1016/j.pnpbp.2006.08.013 · DOI
  109. Miüller, 2007, The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view, J. Neural. Transm., Suppl, 269
  110. Montanari, 2019, Discovery of novel benzofuran-based compounds with neuroprotective and immunomodulatory properties for Alzheimer's disease treatment, Eur. J. Med. Chem., 178, 243, 10.1016/j.ejmech.2019.05.080 · DOI
  111. Moreira, 2009, Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression, Best Pract. Res. Clin. Endocrinol. Metabol., 23, 133, 10.1016/j.beem.2008.09.003 · DOI · Paper page
  112. Moreno-García, 2020, Gene expression analysis of astrocyte and microglia endocannabinoid signaling during autoimmune demyelination, Biomolecules, 10, 10.3390/biom10091228 · DOI
  113. Murphy, 2012, The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation, J. Neuroinflammation, 9, 79, 10.1186/1742-2094-9-79 · DOI
  114. Müller-Vahl, 2008, Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia, Expert Rev. Neurother., 8, 1037, 10.1586/14737175.8.7.1037 · DOI
  115. Navarrete, 2018, Hypoxia mimetic activity of VCE-004.8, a cannabidiol quinone derivative: implications for multiple sclerosis therapy, J. Neuroinflammation, 15, 64, 10.1186/s12974-018-1103-y · DOI
  116. Navarrete, 2020, Effects of EHP-101 on inflammation and remyelination in murine models of Multiple sclerosis, Neurobiol. Dis., 143, 104994, 10.1016/j.nbd.2020.104994 · DOI
  117. Navarro, 2018, Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia, Brain Behav. Immun., 67, 139, 10.1016/j.bbi.2017.08.015 · DOI
  118. Navarro, 2018, Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB, Brain Behav. Immun., 67, 139, 10.1016/j.bbi.2017.08.015 · DOI
  119. Nent, 2019, CB2 receptor deletion on myeloid cells enhanced mechanical allodynia in a mouse model of neuropathic pain, Sci. Rep., 9, 7468, 10.1038/s41598-019-43858-4 · DOI
  120. Nimmerjahn, 2005, Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo, Science, 308, 1314, 10.1126/science.1110647 · DOI · Paper page
  121. Niu, 2017, Activation of dorsal horn cannabinoid CB2 receptor suppresses the expression of P2Y, J. Neuroinflammation, 14, 185, 10.1186/s12974-017-0960-0 · DOI
  122. Noyce, 2012, Meta-analysis of early nonmotor features and risk factors for Parkinson disease, Ann. Neurol., 72, 893, 10.1002/ana.23687 · DOI · Paper page
  123. Ojha, 2016, β-Caryophyllene, a phytocannabinoid attenuates oxidative stress, neuroinflammation, glial activation, and salvages dopaminergic neurons in a rat model of Parkinson disease, Mol. Cell. Biochem., 418, 59, 10.1007/s11010-016-2733-y · DOI · Paper page
  124. Oka, 2007, Identification of GPR55 as a lysophosphatidylinositol receptor, Biochem. Biophys. Res. Commun., 362, 928, 10.1016/j.bbrc.2007.08.078 · DOI · Paper page
  125. Ortega-Alvaro, 2011, Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice, Neuropsychopharmacology, 36, 1489, 10.1038/npp.2011.34 · DOI · Paper page
  126. Ortega-Gutiérrez, 2005, Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis, Faseb. J., 19, 1338, 10.1096/fj.04-2464fje · DOI
  127. Ouali Alami, 2018, NF-κB activation in astrocytes drives a stage-specific beneficial neuroimmunological response in ALS, EMBO J., 37, 10.15252/embj.201798697 · DOI
  128. Passavanti, 2019, Clinical applications of palmitoylethanolamide in pain management: protocol for a scoping review, Syst. Rev., 8, 9, 10.1186/s13643-018-0934-z · DOI
  129. Paszcuk, 2011, Cannabinoid agonists inhibit neuropathic pain induced by brachial plexus avulsion in mice by affecting glial cells and MAP kinases, PloS One, 6, 10.1371/journal.pone.0024034 · DOI
  130. Perry, 1994, Modulation of microglia phenotype, Neuropathol. Appl. Neurobiol., 20, 177
  131. Price, 2009, WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease, Eur. J. Neurosci., 29, 2177, 10.1111/j.1460-9568.2009.06764.x · DOI · Paper page
  132. Puffenbarger, 2000, Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells, Glia, 29, 58, 10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.0.CO;2-W · DOI · Paper page
  133. Racz, 2008, Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain, J. Neurosci., 28, 12125, 10.1523/JNEUROSCI.3400-08.2008 · DOI · Paper page
  134. Raghavendra, 2003, Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy, J. Pharmacol. Exp. Therapeut., 306, 624, 10.1124/jpet.103.052407 · DOI · Paper page
  135. Rahimi, 2015, Interaction between the protective effects of cannabidiol and palmitoylethanolamide in experimental model of multiple sclerosis in C57BL/6 mice, Neuroscience, 290, 279, 10.1016/j.neuroscience.2015.01.030 · DOI
  136. Rahn, 2014, Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery, Mol. Pain, 10, 27, 10.1186/1744-8069-10-27 · DOI
  137. Raman, 2004, Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid, Amyotroph Lateral Scler., 5, 33
  138. Ramírez, 2005, Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation, J. Neurosci., 25, 1904, 10.1523/JNEUROSCI.4540-04.2005 · DOI · Paper page
  139. Renton, 2014, State of play in amyotrophic lateral sclerosis genetics, Nat. Neurosci., 17, 17, 10.1038/nn.3584 · DOI · Paper page
  140. Reyes-Resina, 2018, Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases, Biochem. Pharmacol., 157, 169, 10.1016/j.bcp.2018.06.001 · DOI
  141. Reynolds, 2008, Nitrated alpha-synuclein and microglial neuroregulatory activities, J. Neuroimmune Pharmacol., 3, 59, 10.1007/s11481-008-9100-z · DOI
  142. Ribeiro, 2013, Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis, Neuroscience, 254, 427, 10.1016/j.neuroscience.2013.09.005 · DOI
  143. Roche, 2010, Brain CB₂ receptors: implications for neuropsychiatric disorders, Pharmaceuticals, 3, 2517, 10.3390/ph3082517 · DOI
  144. Rodríguez-Cueto, 2014, Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias, Br. J. Pharmacol., 171, 1472, 10.1111/bph.12283 · DOI
  145. Rolak, 2003, Multiple sclerosis: it's not the disease you thought it was, Clin. Med. Res., 1, 57, 10.3121/cmr.1.1.57 · DOI
  146. Rothstein, 2017, Edaravone: a new drug approved for ALS, Cell, 171, 725, 10.1016/j.cell.2017.10.011 · DOI · Paper page
  147. Río-Hortega, 1919, El tercer elemento de los centros nerviosos I. La microglía en estado normal, Boletín de la Sociedad Española de Biología, 9, 68
  148. Savonenko, 2015, Cannabinoid CB2 receptors in a mouse model of Aβ amyloidosis: immunohistochemical analysis and suitability as a PET biomarker of neuroinflammation, PloS One, 10, 10.1371/journal.pone.0129618 · DOI
  149. Sawada, 2014, Suppression of bone marrow-derived microglia in the amygdala improves anxiety-like behavior induced by chronic partial sciatic nerve ligation in mice, Pain, 155, 1762, 10.1016/j.pain.2014.05.031 · DOI
  150. Schmöle, 2015, Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer's disease mouse model, Neurobiol. Aging, 36, 710, 10.1016/j.neurobiolaging.2014.09.019 · DOI
  151. Schmöle, 2018, Cannabinoid receptor 2-deficiency ameliorates disease symptoms in a mouse model with alzheimer's disease-like pathology, J Alzheimers Dis, 64, 379, 10.3233/JAD-180230 · DOI
  152. Scholz, 2019, The IASP classification of chronic pain for ICD-11: chronic neuropathic pain, Pain, 160, 53, 10.1097/j.pain.0000000000001365 · DOI · Paper page
  153. Sherer, 2003, Selective microglial activation in the rat rotenone model of Parkinson's disease, Neurosci. Lett., 341, 87, 10.1016/S0304-3940(03)00172-1 · DOI · Paper page
  154. Shiue, 2017, Continuous intrathecal infusion of cannabinoid receptor agonists attenuates nerve ligation-induced pain in rats, Reg. Anesth. Pain Med., 42, 499, 10.1097/AAP.0000000000000601 · DOI
  155. Shoemaker, 2007, The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset, J. Neurochem., 101, 87, 10.1111/j.1471-4159.2006.04346.x · DOI · Paper page
  156. Smeyne, 2016, Assessment of the effects of MPTP and paraquat on dopaminergic neurons and microglia in the substantia nigra pars compacta of C57BL/6 mice, PloS One, 11, 10.1371/journal.pone.0164094 · DOI
  157. Solas, 2013, CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients, Neurobiol. Aging, 34, 805, 10.1016/j.neurobiolaging.2012.06.005 · DOI · Paper page
  158. Spillantini, 1997, Alpha-synuclein in lewy bodies, Nature, 388, 839, 10.1038/42166 · DOI · Paper page
  159. Stella, 2010, Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas, Glia, 58, 1017, 10.1002/glia.20983 · DOI · Paper page
  160. Stoll, 1999, The role of microglia and macrophages in the pathophysiology of the CNS, Prog. Neurobiol., 58, 233, 10.1016/S0301-0082(98)00083-5 · DOI · Paper page
  161. Sun, 2007, New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis, Pain, 129, 64
  162. Suárez-Pinilla, 2014, Immune system: a possible nexus between cannabinoids and psychosis, Brain Behav. Immun., 40, 269, 10.1016/j.bbi.2014.01.018 · DOI
  163. Talarico, 2019, Modulation of the cannabinoid system: a new perspective for the treatment of the alzheimer's disease, Curr. Neuropharmacol., 17, 176, 10.2174/1570159X16666180702144644 · DOI
  164. Taylor, 2015, Microglia disrupt mesolimbic reward circuitry in chronic pain, J. Neurosci., 35, 8442, 10.1523/JNEUROSCI.4036-14.2015 · DOI · Paper page
  165. Ternianov, 2012, Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine, Neurobiol. Aging, 33, 421, 10.1016/j.neurobiolaging.2010.09.012 · DOI
  166. Tolon, 2009, The activation of cannabinoid CB2 receptors stimulates in situ and in vitro beta-amyloid removal by human macrophages, Brain Res., 1283, 148, 10.1016/j.brainres.2009.05.098 · DOI
  167. Toth, 2010, Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain, Mol. Pain, 6, 16, 10.1186/1744-8069-6-16 · DOI
  168. Traxinger, 2013, Prognosis and epidemiology of amyotrophic lateral sclerosis: analysis of a clinic population, 1997-2011, Neurol Clin Pract, 3, 313, 10.1212/CPJ.0b013e3182a1b8ab · DOI
  169. Tsuda, 2005, Neuropathic pain and spinal microglia: a big problem from molecules in "small" glia, Trends Neurosci., 28, 101, 10.1016/j.tins.2004.12.002 · DOI · Paper page
  170. Tsuda, 2003, P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury, Nature, 424, 778, 10.1038/nature01786 · DOI · Paper page
  171. Viscomi, 2009, Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway, J. Neurosci., 29, 4564, 10.1523/JNEUROSCI.0786-09.2009 · DOI · Paper page
  172. Walsh, 2011, Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat, Neuroscience, 175, 251, 10.1016/j.neuroscience.2010.12.005 · DOI
  173. Walter, 2003, Nonpsychotropic cannabinoid receptors regulate microglial cell migration, J. Neurosci., 23, 1398, 10.1523/JNEUROSCI.23-04-01398.2003 · DOI · Paper page
  174. Wang, 2020, Spinal cannabinoid receptor 2 activation reduces hypersensitivity associated with bone cancer pain and improves the integrity of the blood-spinal cord barrier, Reg. Anesth. Pain Med., 45, 783, 10.1136/rapm-2019-101262 · DOI
  175. Wen, 2018, WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms, J. Neuroinflammation, 15, 9, 10.1186/s12974-017-1045-9 · DOI
  176. Wen, 2015, Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis, Neuropharmacology, 99, 196, 10.1016/j.neuropharm.2015.07.010 · DOI
  177. Weydt, 2005, Neuroinflammation in the pathogenesis of amyotrophic lateral sclerosis, Neuroreport, 16, 527, 10.1097/00001756-200504250-00001 · DOI
  178. Whyte, 2009, The putative cannabinoid receptor GPR55 affects osteoclast function in vitro and bone mass in vivo, Proc. Natl. Acad. Sci. U. S. A., 106, 16511, 10.1073/pnas.0902743106 · DOI · Paper page
  179. Witting, 2006, Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection, Proc. Natl. Acad. Sci. U. S. A., 103, 6362, 10.1073/pnas.0510418103 · DOI
  180. Woolf, 2010, What is this thing called pain?, J. Clin. Invest., 120, 3742, 10.1172/JCI45178 · DOI · Paper page
  181. Wu, 2013, Activation of the CB2 receptor system reverses amyloid-induced memory deficiency, Neurobiol. Aging, 34, 791, 10.1016/j.neurobiolaging.2012.06.011 · DOI · Paper page
  182. Wu, 2019, Cannabinoid type 2 receptor system modulates paclitaxel-induced microglial dysregulation and central sensitization in rats, J. Pain, 20, 501, 10.1016/j.jpain.2018.10.007 · DOI
  183. Wu, 2017, Activation of CB, Eur. J. Pharmacol., 811, 12, 10.1016/j.ejphar.2017.05.044 · DOI
  184. Xu, 2016, Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats, Eur. J. Neurosci., 44, 3046, 10.1111/ejn.13414 · DOI
  185. Yang, 2019, Activation of spinal macrophage-inducible C-type lectin induces mechanical allodynia and microglial activation in rats, Neurosci. Lett., 690, 42, 10.1016/j.neulet.2018.10.017 · DOI
  186. Yaqub, 2015, Pain in the USA: states of suffering, Lancet, 386, 839, 10.1016/S0140-6736(15)00041-0 · DOI
  187. Yiangou, 2006, COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord, BMC Neurol., 6, 12, 10.1186/1471-2377-6-12 · DOI · Paper page
  188. Yum, 2009, Clinical perspectives on autoimmune processes in schizophrenia, Psychiatr. Clin., 32, 795
  189. Zamberletti, 2015, Cortical neuroinflammation contributes to long-term cognitive dysfunctions following adolescent delta-9-tetrahydrocannabinol treatment in female rats, Eur. Neuropsychopharmacol, 25, 2404, 10.1016/j.euroneuro.2015.09.021 · DOI
  190. Zanelati, 2010, Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors, Br. J. Pharmacol., 159, 122, 10.1111/j.1476-5381.2009.00521.x · DOI · Paper page
  191. Zhang, 2011, Cannabinoid receptor and N-acyl phosphatidylethanolamine phospholipase D--evidence for altered expression in multiple sclerosis, Brain Pathol., 21, 544, 10.1111/j.1750-3639.2011.00477.x · DOI
  192. Zhang, 2007, Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model, J. Cerebr. Blood Flow Metabol., 27, 1387, 10.1038/sj.jcbfm.9600447 · DOI · Paper page
  193. Zhang, 2007, Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein, Glia, 55, 1178, 10.1002/glia.20532 · DOI · Paper page
  194. Zhou, 2017, Microglia polarization with M1/M2 phenotype changes in rd1 mouse model of retinal degeneration, Front. Neuroanat., 11, 77, 10.3389/fnana.2017.00077 · DOI · Paper page
  195. Zoccolella, 2009, Current and emerging treatments for amyotrophic lateral sclerosis, Neuropsychiatric Dis. Treat., 5, 577, 10.2147/NDT.S7788 · DOI

Cited by

See all 94

Metadata

Authors
Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem-Taylor, G.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2021-06
Volume
190
Pages
108555
ISSN
0028-3908
Cited by
94
References
65
Language
en
Funders
National Health and Medical Research Council (APP1162060)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The cannabinoid system and microglia in health and disease. https://app.cochat.ai/papers/10.1016/j.neuropharm.2021.108555
The paper
Duffy, S. S., Hayes, J. P., Fiore, N. T., & Moalem-Taylor, G. (2021). The cannabinoid system and microglia in health and disease. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2021.108555

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.